Tag: Mirvaso

Mirvaso® approved by European Commission

Galderma has announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel. Mirvaso is an alpha-2 adrenergic receptor agonist that acts rapidly and can...

Read More
Loading

Login Status

March/April 2024 Issue

Upcoming Events

There are no upcoming events.